Vivani Medical and Novo Nordisk Sign Non-Exclusive Agreement for Novo to Evaluate NPM-139, a Once- or Twice-Yearly Semaglutide Implant
On July 7, Vivani Medical announced a non-exclusive agreement letting Novo Nordisk evaluate NPM-139, a miniature ultra-long-acting semaglutide implant built on Vivani's NanoPortal technology and designed for once- or twice-yearly dosing. The deal grants no exclusivity over NPM-139 or the NanoPortal platform. It follows a June 25 Australian ethics-committee clearance for SLIM-1, a Phase 1 trial of NPM-139 that builds on Vivani's earlier NPM-119 exenatide implant.